{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:45:36Z","timestamp":1788273936826,"version":"build-2803163510"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n\u2009=\u2009347), or PRP (n\u2009=\u2009342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20\/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs \u22124.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04278417?cond=NCT04278417&amp;amp;amp;rank=1\">NCT04278417<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.1008","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:30:36Z","timestamp":1776958236000},"page":"500","source":"Crossref","is-referenced-by-count":1,"title":["Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy"],"prefix":"10.1001","volume":"144","author":[{"given":"Sebastian","family":"Wolf","sequence":"first","affiliation":[{"name":"Bern Photographic Reading Center, Department of Ophthalmology, University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Bellaire"},{"name":"Retina Consultants of America, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Emanuelli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Salehi-Had","sequence":"additional","affiliation":[{"name":"Retina Associates of Southern California, Huntington Beach"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Yan","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for BioMedical Research Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Kovacic","sequence":"additional","affiliation":[{"name":"Novartis AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Novartis AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"eoi260018r1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/life13051098","article-title":"Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy.","volume":"13","author":"Bahr","year":"2023","journal-title":"Life (Basel)"},{"issue":"11","key":"eoi260018r2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis.","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"16","key":"eoi260018r3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMct0908432","article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy.","volume":"365","author":"Bressler","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi260018r4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/08820538.2017.1353820","article-title":"Panretinal photocoagulation: a review of complications.","volume":"33","author":"Reddy","year":"2018","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"eoi260018r5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2005.02.029","article-title":"Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision.","volume":"140","author":"Shimura","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi260018r6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.ophtha.2018.04.039","article-title":"Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: factors associated with vision and edema outcomes.","volume":"125","author":"Bressler","year":"2018","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi260018r7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"eoi260018r8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1144422","article-title":"Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.","volume":"14","author":"Xie","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10085","key":"eoi260018r9","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"eoi260018r10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ophtha.2018.08.001","article-title":"Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy.","volume":"126","author":"Sun","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi260018r11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration.","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi260018r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"key":"eoi260018r13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema.","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"eoi260018r14","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"39","key":"eoi260018r15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034856","article-title":"Efficacy and safety of pan retinal photocoagulation combined with intravitreal anti-VEGF agents for high-risk proliferative diabetic retinopathy: a systematic review and meta-analysis.","volume":"102","author":"Fu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"eoi260018r16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/ICU.0000000000000799","article-title":"Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA.","volume":"32","author":"Nanegrungsunk","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"eoi260018r17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ophtha.2016.12.005","article-title":"Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab.","volume":"124","author":"Bressler","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi260018r18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/08820538.2023.2271095","article-title":"Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis.","volume":"39","author":"Abu Serhan","year":"2024","journal-title":"Semin Ophthalmol"},{"issue":"12","key":"eoi260018r19","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","article-title":"Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial.","volume":"141","author":"Singh","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi260018r20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi260018r21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial.","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2847704\/jamaophthalmology_wolf_2026_oi_260018_1781021773.36622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:01:07Z","timestamp":1781794867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2847704"}},"subtitle":["The CONDOR Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.1008","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}